Comment from RD Research Services, LLC + Max Output, LLC + Amal Dadi

Summary: Representatives from RD Research Services, LLC, Max Output, LLC, and an independent consultant provide detailed feedback on the FDA's AI-enabled clinical trials pilot program. They support the initiative but emphasize the need for robust regulatory engagement, clear liability frameworks, and specific metrics for safety, data integrity, and model performance to protect human subjects.